If a proposed treatment has both a drug (or biologic) and device component, the FDA may consider it a combination product. Examples of possible combination products are asthma inhalers, drug delivery patches, collagen implants, and drug-eluting stents. The FDA may decide to treat a combination product as a drug or as a device, and that determination will affect the IRB review.